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Background: Type 2 diabetes has been associated with increased incidence of atrial fibrillation (AF) and
cardiovascular disease. Controversy remains regarding the role of insulin in the epidemiology of AF risk. The aim of
the present study was to study the association between fasting plasma insulin (FPI) and incidence of AF, as well as
any effect modification by fasting blood glucose (FBG) or 2 h post-load blood glucose and body mass index (BMI).
Methods: The study population consisted of 6052 men and 1014 women followed for an average of 26.2 years.
There were 983 cases of incident AF. Analysis was performed using Cox regression and competing risks regression
approaches. The population was analysed as a whole, and by subgroups according to glucose levels and BMI.
Results: After adjustment for age, height, weight, systolic blood pressure and smoking there was a significant inverse
association between FPI and AF (hazard ratio; HR) for 4th vs. 1st quartile: 0.69 (95% confidence interval (CI): 0.57-0.83,
p < 0.0001) in the cohort as a whole. Among men the corresponding values were HR 0.64 (95% CI 0.52-0.78, p < 0.001)
and among women HR 1.16 (95% CI 0.69-1.93, p = 0.58); p-value for interaction 0.06. The protective effects of insulin
tended to be weaker in subjects with elevated fasting glucose, implying that the relation between FPI and incident AF
could be dependent on the status of individual’s glucose metabolism.
Conclusions: High levels of FPI are associated with lower risk of incident AF in a middle-aged population with a long
follow-up.
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Atrial fibrillation (AF) is a well-documented public health
concern causing substantial mortality and morbidity [1].
Known risk factors include age, male gender, hypertension
and heart disease [2]. However, the established risk factors
for AF can only account for approximately half of the AF
cases in the population [2-4]. Novel approaches to risk
factor screening are thus warranted. A recent meta-
analysis has shown diabetes to be a risk factor for AF [5],
but controversy remains as to the mechanism involved.
There is some evidence that lack of glycemic control in-
creases risk [6,7]. Insulin has been shown to be a risk fac-
tor for cardiovascular disease [8] and overall mortality
[9]. It is, however, not clear whether insulin or insulin* Correspondence: linda.johnson@med.lu.se
Department of Clinical Sciences, Lund University, Skåne University Hospital,
Inga-Marie Nilssons väg 49, 20502 Malmö, Sweden
© 2014 Johnson et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.resistance are risk factors for AF. In the Framingham co-
hort no significant association was found between insulin
resistance and AF [10] and in the ARIC study no positive
relation was found between fasting plasma insulin (FPI)
and AF risk [6]. On the contrary, several studies have
shown that the metabolic syndrome, wherein insulin
resistance is a crucial component, is related to incidence
of AF [11-15]. Thus, some controversy remains regarding
the role of insulin in the epidemiology of AF.
Insulin exerts an effect on the vasculature through
specific endothelial insulin receptors. The relationship
between insulin and the endothelium is complex, and
has been shown to vary according to whether the subject
is insulin resistant or not [16,17]. In the case of normal
insulin sensitivity the effect of the endothelium is to lower
blood pressure and enhance blood flow [17] through release
of nitric oxide (NO). However, in the insulin resistantl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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causing vasoconstriction instead and subsequent blood
pressure elevation [16]. Therefore, as hemodynamic factors
are important risk factors for AF the relationship between
insulin and AF could vary according to the individual’s de-
gree of insulin sensitivity and glycaemic control.
Since AF is mainly a disease of the elderly [1,2] the rela-
tionship between insulin and cardiovascular mortality
could introduce bias in a study that uses conventional
Cox regression analysis of the relation between insulin
and AF; e.g. subjects that die of other causes are no longer
at risk of AF. This problem can be addressed by using the
competing risks approach described by Fine and Gray [18]
plotting the sub-hazard of individual risk factors.
The Malmö Preventive Project (MPP) is a large population-
based cohort with a long follow-up time, with partici-
pants recruited through invitation of individuals born
in pre-specified years and living in the city of Malmö,
Sweden [19]. The present study aimed to investigate
the relationship between FPI and incident AF in the
MPP, using conventional Cox regression as well as
competing risks regression approaches. Furthermore,
since there could be an interaction between blood glu-
cose or obesity on the one hand and insulin on the
other for AF risk we wished to examine whether the
effect of FPI might differ across strata of FBG, 2 h BG
and body mass index (BMI).
Methods
Study population
The MPP cohort was created at the Department of
Preventive Medicine at the University Hospital in
Malmö in 1974. It has been described in detail elsewhere
[20]. Between the years 1974 and 1992 a total of 22,444
men and 10,902 women participated in the screening (70%
attendance rate). The aim was to screen a large proportion
of the population and provide intervention to high-risk in-
dividuals. Middle-aged men and women born in pre-
specified years were invited to participate. The health
screening included physical examination, blood sampling,
spirometry and a self-administered questionnaire. Inter-
ventions (lifestyle modification, drug therapy) were of-
fered to nearly 25% of screened individuals, but there
was no significant effect in general on cardiovascular
mortality and on overall morbidity [19]. Men were
screened mostly during 1974–1982 and women mostly
during 1977–1992, but for both genders FPI was mea-
sured mainly between 1975–1979, which accounts for
the smaller sample size for women.
The study population for the present study was de-
rived from a subgroup of the MPP cohort whose blood
samples were analysed for FPI (n = 7298). We excluded
11 cases of prevalent AF and 213 cases of prevalent dia-
betes at baseline, as well as 1 individual with missingdata for smoking status and 7 individuals with missing
data for SBP. The study finally included 6052 men and
1014 women. In subgroups by FBG levels individuals
with prevalent diabetes were included.Data collection
Height (m) was measured using a fixed stadiometer; weight
(kg) was measured in light indoor clothing using a balance
beam scale. Systolic blood pressure (SBP) (mmHg) was
measured twice after 10 min of supine rest, using a sphyg-
momanometer with a modifiable cuff. Blood samples were
drawn after overnight fast and analysed at the Department
of Clinical Chemistry, Malmö University Hospital. FBG
was analysed using the glucose-oxidase method (1974 to
1977) or the hexokinase-oxidase method (1977 to 1992).
These two methods give similar results which were there-
fore used as such without a conversion factor. FPI was ana-
lysed by a nonspecific radioimmunoassay (RIA) method
[21] with a detection limit at 3 mIU L−1 (nmol L−1 =mIU
L−1 × 7.175/1000). The Department of Clinical Chemistry
in Malmö, where the RIA method was originally developed
was attached to a continuing standardization program. In-
dividuals who reported that they were currently smoking
were classified as smokers. An oral glucose tolerance test
(OGTT; 30 g glucose in/ m2 body surface at the beginning
of the study and a fixed dose of 75 g in the later part of the
study) was performed after an overnight fast in randomly
selected age cohorts within the study population: in total
5476 (90%) men and 896 (88%) women of the study popu-
lation. Blood samples were drawn immediately before and
after 120 min rest post-OGTT. Sedentary life-style was de-
fined as a positive answer to the question “Are you mostly
sedentary in your spare time”. Alcohol risk use was
assessed as two or more positive answers to the Malmö
modification of the Michigan Alcohol Screening Test
(MM-MAST) [22] and low socioeconomic status was de-
fined as Statistics Sweden socioeconomic index (SEI) group
11–36.National registries
End points were retrieved through linkage with the
Swedish Hospital Discharge Register, which is adminis-
tered by The Swedish National Board of Health and
Welfare. A recent validation study showed that the diag-
nosis of AF or atrial flutter had very high case validity in
this register [3]. Participants were followed until first
episode of AF (diagnosis codes 427D for the 9th revision
of International Classification of Diseases, ICD-9, and
I48 for the 10th revision, ICD-10), or until censoring by
death or emigration from Sweden. Follow-up ended at
June 30th 2009. AF and atrial flutter have not been dis-
tinguished due to the similarities of these diagnoses [23].
The study complied with the declaration of Helsinki and
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in Lund (number 85/ 2004).Statistics
All analyses were carried out using STATA for Windows
version 12.1, excepting sample size calculations which were
analysed using the cohort power function in EPISHEET by
Rothman (available at http://www.epidemiolog.net). Vari-
ables with a positively skewed distribution (FPI and FBG)
were log-transformed. FPI was analysed as a continuous
variable (per log unit) and in quartiles, using Cox regres-
sion and competing risks regression. The population was
further analysed stratified on gender, BMI group and FBG
interval. In order to evaluate the degree of confounding by
baseline SBP and smoking status we fitted two models;
Model 1 adjusted for age, sex, height and weight and,
Model 2 further adjusted for SBP, and current smoking
status. The inclusion of variables assessing total choles-
terol, triglycerides, sedentary lifestyle, alcohol use and
low socioeconomic status did not substantially change
the results and these factors were therefore omitted
from the final model. In order to evaluate whether
changes in screening procedures or calendar time at
screening influenced the results we tested whether
screening year was associated with outcome. Since it
was not it was excluded from the final model.
Models testing for interaction between FPI on the one
hand and FBG, BMI, SBP, smoking status, gender and
age on the other were fitted, and the models with inter-
action parameters were tested against those without
using likelihood ratio test. Except for gender, for which
the interaction parameter was borderline significant,
there were no significant interaction parameters, nor any
significant differences between models with or without
interaction parameters as assessed by the likelihood ratio
test. A gender stratified analysis was performed, as well
as sample size calculations for women.
The proportionality assumption of cox regression was
assessed visually using Nelson-Aalen plots. A two-sided
p-value of <0.05 was considered significant.Results
Mean follow up was 26.2 years (26.2 years for men and
26.9 years for women), median follow up 30.2 years and
inter-quartile range 9.0 years. During this time there
were 983 cases of incident AF (875 men and 108
women). Men who received a diagnosis of AF did so
after a mean follow-up of 23.4 years, and women after a
mean follow-up of 22.9 years. Mean age ± standard devi-
ation at baseline (SD) was 47.2 ± 2.4 for men and 48.3 ±
6.5 years for women. Fifty-one percent of men and 36%
of women were current smokers at baseline. Mean SBP
was 130 mm Hg for men and 122 mmHg for women.Baseline characteristics by quartiles of FPI are reported
in Table 1.
Fasting insulin and prediction of AF
There was a statistically significant inverse association
between FPI and incident AF after adjustment for Model
1 covariates, (age, gender, height and weight) as well as
after further adjustment in Model 2 (for SBP and smok-
ing status), with HR for 4th vs. 1st quartile: 0.64 (95%
CI: 0.52-0.78, p < 0.0001). Results of the analysis using
Cox regression are presented in Table 2. There was no
substantial difference in results using Cox regression or
competing risks regression (Table 3). The association
between FPI and incidence of AF was found using the
variable as continuous as well as divided into quartiles
(Q1-Q4), (p for trend <0.0001). HR (4th vs 1st quartile)
was 0.60 (95% CI 0.45-0.80) for individuals below me-
dian age (47.6 years) and 0.80 (95% CI 0.61-1.03) for those
above the median age. There was no significant inter-
action between insulin and age with respect to incidence
of AF (p = 0.75). In a gender-stratified analysis, the associ-
ation between FPI and AF was present among men, but
not among women. Sample size calculations showed that
with the current number of included women and the
assumption of the same HR comparing the top to the
bottom quartile among women as observed among men
(0.66) the probability of detection was underpowered at
0.27. The probability of detecting a HR of 0.8 was only
0.12. The interaction parameter between gender and FPI
was borderline significant, p = 0.06.
Risk of AF in relation to fasting insulin and categories of
glycaemic control
In Table 4 the association between FPI and AF stratified
by 2 h glucose values post-OGTT is presented. FPI was
associated with a lower risk of AF in all quartiles (Q1-
Q4) of 2 h glucose, but only findings in Q1-Q2 were
statistically significant. The p-value for interaction be-
tween 2 h glucose and FPI was not significant, p = 0.44.
We also performed analyses including cases of preva-
lent diabetes and stratified by FBG, (Additional file 1:
Table S1). Among individuals with a FBG at or above
6.5 mmol/L, FPI was associated with a borderline signifi-
cantly increased incidence of AF with HR per 1 log unit:
2.04 (95% CI: 0.94-4.44, p = 0.072). The interaction par-
ameter between FBG and FPI was not statistically signifi-
cant (p = 0.95).
Risk of AF stratified for categories of BMI
Analyses were also performed stratified by BMI catego-
ries. The association between insulin and incident AF
was strongest among individuals in the third quartile of
BMI (BMI Q3: 24.3-26.6 kg/m2), with HR 0.62 (95% CI:
0.52-0.75, p < 0.0001). There was no indication of an
Table 1 Baseline characteristics by quartiles of fasting plasma insulin
Men Women
Q 1 Q2 Q3 Q4 Q 1 Q2 Q3 Q4
Number 1,423 1,718 1,383 1,528 410 119 258 227
FPI, mmol/ L, range 1-3 4-8 9-13 14-260 2-3 4-5 6-10 11-62
Age, years 47.0(2.5) 47.1(2.4) 47.3(2.6) 47.6(2.1) 47.8(6.1) 47.9(7.1) 48.1(6.9) 49.6(6.4)
Height, cm 176.2 (6.7) 176.3 (6.4) 176.6 (6.6) 176.5 (6.7) 163.4 (5.8) 164.2 (5.8) 163.4 (6.0) 163.2 (5.8)
Weight, kg 73.6 (10.1) 75.5 (9.9) 77.7(10.8) 82.9 (13.1) 62.0(9.4) 62.1(9.7) 63.3(9.9) 70.5 (15.6)
BMI, kg/m2 23.7 (2.7) 24.3 (2.8) 24.8 (3.0) 26.6 (3.8) 23.2 (3.3) 23.1 (3.5) 23.7 (3.5) 26.4 (5.4)
FBG, mmol/L 4.8 (0.49) 4.9 0.53) 4.9 (0.56) 4.9 (0.60) 4.8 (0.49) 4.8 (0.51) 4.8 (0.48) 5.0 (0.48)
Blood glucose at 2 h OGTT 5.2 (1.3) 5.3 (1.4) 5.5 (1.4) 5.9 (1.6) 6.0 (1.4) 6.1 (1.4) 6.6 (1.6) 6.6 (1.5)
SBP, mmHg 127(16) 128(15) 130(16) 134 (17) 121 (15) 123 (17) 122 (16) 126 (16)
Current smoking,% 54.5 52.0 51.2 47.7 36.3 38.7 34.1 37.7
Values are means (standard deviation) unless otherwise stated.
FPI = Fasting Plasma Insulin, FBG = Fasting blood glucose, OGTT = Oral Glucose Tolerance Test, SBP = Systolic Blood pressure, BMI = Body Mass Index.
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(Q2: 22.5-24.2 kg/m2), HR 0.99 (95% CI: 0.82-1.20, p =
0.89) and top quartiles (Q4: >26.6 kg/m2 ); HR 0.95
(95% CI: 0.85-1.10, p = 0.50). The interaction parameters
between BMI and FPI were not significant, p = 0.42.
(Additional file 1: Table S1).
In order to address possible confounding by prevalent
and incident coronary artery disease (CAD) and congest-
ive heart failure (HF) we performed a subanalysis in
which individuals with known CAD or CHF at baseline
were excluded, and individuals were censored at the time
of a CAD or CHF event. Results were not substantially al-
tered in this subgroup, for men the HR comparing the 4thTable 2 Hazard ratios for fasting plasma insulin in relation to
Model 1
HR 95% CI
Both genders Ln-Insulin 0.82 0.75-0.90
Quartile 1 reference
Quartile 2 0.95 0.80-1.11
Quartile 3 0.75 0.62-0.90
Quartile 4 0.71 0.59-0.86
Men Ln-Insulin 0.81 0.73-0.89
Quartile 1 reference
Quartile 2 0.90 0.75-1.08
Quartile 3 0.72 0.59-0.88
Quartile 4 0.66 0.54-0.81
Women Ln-Insulin 0.98 0.74-1.31
Quartile 1 reference
Quartile 2 1.24 0.68-2.29
Quartile 3 0.94 0.56-1.57
Quartile 4 1.18 0.71-1.96
Based on 7066 individuals (6052 men and 1014 women) and 983 cases. Model 1 is
adjusted for Model 1 covariates + systolic blood pressure and smoking status. HR foto the 1st quartile of FPI was 0.67, (95% CI 0.54-0.82, p <
0.0001).
A model adjusting for Model 2 co-variates as well as
total cholesterol and triglycerides was tested, without
any substantial change in the effect measure between
FPI and incident AF; per log unit of FPI HR 0.81, (95%
CI: 0.74-0.89, p < 0.0001).
Discussion
The presented population-based cohort with a long
follow-up of middle-aged individuals found a statistically
significant inverse association between FPI and incident
AF. This association remained significant after adjustingincidence of AF
Model 2
P HR 95% CI P
<.0001 0.81 0.74.0.88 <.0001
0.54 0.95 0.80-1.13 0.54
0.002 0.74 0.62-0.89 0.002
<.0001 0.69 0.57-0.84 <.0001
<.0001 0.79 0.72-0.87 <.0001
0.28 0.91 0.76-1.08 0.28
0.001 0.71 0.58-0.86 0.001
<.0001 0.64 0.52-0.78 <.0001
0.91 0.97 0.72-1.30 0.86
0.48 1.21 0.66-2.22 0.55
0.82 0.95 0.57-1.59 0.85
0.52 1.16 0.69-1.93 0.58
adjusted for age, sex (where applicable), height and weight. Model 2 is
r Ln-insulin is expressed per 1 log unit.
Table 3 Fasting plasma insulin and incidence of AF analysed with competing risks regression considering mortality as
a competing event
Model 1 Model 2
SHR 95% CI P SHR 95% CI P
Both genders Ln-Insulin 0.81 0.74-0.88 <.0001 0.80 0.73-0.88 <.0001
Quartile 1 reference
Quartile 2 0.99 0.83-1.18 .89 0.99 0.83-1.17 .89
Quartile 3 0.78 0.65-0.94 0.008 0.78 0.64-0.93 0.007
Quartile 4 0.69 0.57-0.84 <.0001 0.69 0.57-0.83 <.0001
Men Ln-Insulin 0.80 0.73-0.88 <.0001 0.80 0.72-0.87 <.0001
Quartile 1 reference
Quartile 2 0.95 0.79-1.14 0.59 0.95 0.80-1.14 0.60
Quartile 3 0.75 0.62-0.92 0.005 0.75 0.62-0.92 0.005
Quartile 4 0.66 0.54-0.81 <.0001 0.65 0.53-0.80 <.0001
Women Ln-Insulin 0.89 0.69-1.15 0.39 0.87 0.68-1.13 0.31
Quartile 1 reference
Quartile 2 1.25 0.68-2.31 0.47 1.22 0.66-2.26 0.52
Quartile 3 0.94 0.57-1.57 0.82 0.94 0.56-1.57 0.82
Quartile 4 1.02 0.61-1.70 0.93 0.98 0.59-1.64 0.95
Based on 7066 individuals (6052 men and 1014 women) and 983 cases. Model 1 is adjusted for age, sex (where applicable), height and weight. Model 2 is
adjusted for Model 1 covariates + systolic blood pressure and smoking status. SHR for ln-Insulin is expressed per log unit. SHR = sub-hazards ratio from a competing
risk regression.
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blood pressure and smoking status (Tables 2 and 3).
[24-26] We also ruled out confounding by total choles-
terol, triglycerides, low socioeconomic status, physical
inactivity and risk over-use of alcohol before excluding
these factors from the final model. There was a border-
line significant evidence of an interaction between gen-
der and FPI, and no significant association between FPI
and AF was found among women in a gender stratified
analysis, but in the context of the relatively small sample
size of women further study would be needed to assess
whether this was due to lack of statistical power among
women or a true lack of association among women.
Following adjustment FPI displayed an inverse linear
relationship with incident AF among normoglycemic
men. Therefore, we conclude that in the MPP cohort
high levels of FPI at baseline confer a decreased risk ofTable 4 Hazard ratios per unit increase in ln-fP-Insulin and in
post-OGTT
Model 1
HR 95% CI P N AF e
Q1 BG = 1.9-4.4 0.80 0.65-0.99 0.038 1552 219
Q2 BG = 4.5-5.4 0.81 0.66-0.98 0.033 1600 219
Q3 BG = 5.5-6.4 0.87 0.72-1.05 0.16 1708 235
Q4 BG ≥6.5 0.87 0.73-1.05 0.14 1691 238
Cases of prevalent diabetes included for these sub-analyses.
Model 1 is adjusted for age, sex, height and weight. Model 2 is adjusted for Mode
Cox regression. BG= Blood Glucose.incident AF during follow-up in the population as a
whole and among normoglycemic men.
The inverse association between insulin and AF was
somewhat weaker in subjects with high 2 h glucose post-
OGTT in the top quartile, and a positive association was
observed in subjects with high fasting blood glucose,
which was close to statistical significance. There were no
statistically significant interaction parameters between
FBG or 2 h glucose post OGTT on the one hand and FPI
on the other. These results could thus be due to chance,
but it would be interesting to examine whether the associ-
ation between FPI and AF risk, could be dependent on the
degree of the subject’s glycaemic control in a larger sample
with a higher proportion of subjects with high glucose
values.
The results of the present study differ from the results
of the ARIC study, which found no significant associationcidence of AF; subgroups by quartile of 2 h glucose
Model 2
vents HR 95% CI P N AF events
0.78 0.64-0.97 0.022 1551 219
0.80 0.66-0.97 0.025 1600 219
0.86 0.71-1.04 0.12 1708 235
0.86 0.72-1.03 0.091 1691 238
l 1 covariates + systolic blood pressure and smoking status. Analysed using
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of the ARIC study was 57 years; roughly ten years older
than subjects of the present study at baseline. The mean
BMI in the ARIC study was higher as well, corresponding
to the top quartile in the present study, where the inverse
association between FPI and AF in our data appeared
weakest, and was not statistically significant. Therefore, it
could be that the results in the ARIC cohort differed from
the present study because that study included a higher
proportion of individuals with disturbed glucose metabol-
ism, in whom FPI tended to be associated rather with an
increased risk of AF, thus tending to nullify the overall risk
of insulin. The same argument holds true for the Framing-
ham study which reported no relationship between insulin
resistance and incident AF in subjects with a mean age of
59 years and a mean BMI of 27.4 kg/m2[10].
The MPP cohort thus examines the relationship be-
tween FPI and incident AF in a younger and healthier co-
hort as compared to the ARIC and Framingham cohorts.
It can therefore be assumed that the MPP includes a lar-
ger proportion of individuals in a strictly normoglycemic
state as compared to the other studies. This may be of im-
portance since the effects of insulin on the vasculature
have been shown to vary according to whether the indi-
vidual is insulin resistant or not [16].
Insulin acts on the vasculature through specific endo-
thelial insulin receptors. It is well known that the insulin
hormone normally has a vasodilator effect [27], and in-
creases skeletal blood flow [28]. This effect is mediated
through NO [29] following signaling through the phos-
phatidylinositol 3-kinase - dependent (PI3K) pathway,
and can be inhibited by use of a competitive inhibitor of
nitric acid synthase [30]. Further proof of the vasodilator
effect of insulin is that insulin sensitizing drugs such as
glitazones (thiazolidinediones) have a well-known, albeit
small, blood pressure lowering side-effect [31,32]. In in-
sulin resistance, however, PI3K mediated signaling is im-
paired, resulting in vasoconstriction [33,34].
It is well documented that blood pressure is an im-
portant AF risk factor, including high normal blood
pressure [35-38]. Furthermore, it has recently also been
shown that low insulin secretion is associated with in-
creased incidence of hypertension in studies of families
at genetic risk of type 2 diabetes [39]. It is therefore pos-
sible that different actions of insulin on the vasculature
and hemodynamic regulation, and thereby the blood
pressure levels, could contribute to explain the results of
the present study. It is also possible that these effects
could differ between individuals with impaired or nor-
mal insulin sensitivity.
The findings of the present study could be of importance
for the understanding of the relation between disturbed
glucose metabolism, insulin regulation and sensitivity, and
AF risk. To the best of our knowledge the MPP is the firstcohort study to examine the relationship between FPI and
AF in relation to shifting glycaemic control.
Strengths and limitations
The high participation rate, large size and long follow-
up represent strengths of this study, as well as the high
quality and proven validity of the Swedish National Hos-
pital Discharge register [3]. We have controlled for many
known risk factors for AF, and ruled out confounding by
others. However, we still cannot rule out residual con-
founding, for example influences by thyroid disease,
sleep apnea or valvular heart disease. Given the relatively
low mean age of the cohort, any such confounding can
be assumed to be small, however, and not on a scale to
influence results. We have adjusted for height and
weight, but it is possible that another measure of body
composition, such as waist circumference, would have
accounted for the possible confounding from body com-
position on the association between FPI and AF better,
and that some residual confounding remains.
Cases with AF were retrieved from the Swedish Hos-
pital discharge register. A recent validation study showed
that case validity of this diagnosis is very high [3]. This
register has been operating in southern Sweden during
the entire follow-up period and became nation-wide in
1987. However, many AF patients are treated as outpa-
tients without any hospitalization and these cases have
been missed. Prevalent cases were retrieved from the
same database. We cannot rule out that some individ-
uals with subclinical and undetected AF at baseline
could have erroneously been included in the study, how-
ever, given the relatively low mean age of the cohort this
number can be assumed to be small.
Conclusions
The present study found an inverse association between
FPI and risk of incident AF during long-term follow-up
for the population as a whole and among men. This asso-
ciation is not explained by previously known risk factors
for AF. Further study of the glucose-dependent relation
between insulin and incident AF risk is warranted.
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